Emergent BioSolutions (EBS) Issues 2022 Guidance; Reports Prelim FY21 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
January 9, 2022 2:00 PM ESTExpects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA margin of 21.5% at the midpointReports preliminary 2021 total revenues of $1.78 billion at the midpoint and Adjusted EBITDA of $513 million, or 29%, at the midpoint, both in line with prior guidance given in November 2021
GAITHERSBURG, Md., Jan. 09, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced its financial guidance for 2022 and selected preliminary unaudited financial results for 2021.
This past year we... More
